Epidemiological study of Hidradenitis Suppurativa (HS) to determine the prevalence and severity of the disease in the Australian population.

Not Applicable

Completed

• Conditions: Hidradenitis Suppurativa; Skin - Dermatological conditions

• Registration Number: ACTRN12615000812594
• Lead Sponsor: AbbVie Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-08-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 7000

Inclusion Criteria

All those who participates in the 'Single Source Survey'.

Exclusion Criteria

Those who are under 18 years of age and have not consented to the 'Single Source Survey' .

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of HS - based on dermatologist diagnosis of HS, and the statistical analysis of the number of diagnoses in the Australian population. [Measured after a dermatologist has reviewed a patient for HS and confirmed diagnosis, and a central expert dermatologist has reviewed all cases for consistency in diagnosis. Statistical analysis of the data collected will be then be conducted to determine prevalence. Anticipated to be a month after all surveys are conducted. ]

Secondary Outcome Measures

Name	Time	Method
Severity of HS via Hurley Stage method - based on dermatologist diagnosis of moderate to severe HS, and the statistical analysis of the number of moderate to severe cases in the Australian population. [Measured after a dermatologist has reviewed a patient for HS, confirmed diagnosis, provided severity as per the Hurley Stage Method, and a central expert dermatologist has reviewed all cases for consistency in severity grading. Statistical analysis of the data collected will be then be conducted to determine severity in the Australian population. Anticipated to be a month after all surveys are conducted. ]